Boston Scientific Investor Update Summary Company and Industry - **Company**: Boston Scientific (NYSE: BSX) - **Acquisition Target**: Penumbra Core Points and Arguments - **Acquisition Announcement**: Boston Scientific announced an agreement to acquire Penumbra for $15 billion, with a purchase price of $374 per share in cash and stock [5][11] - **Strategic Fit**: The acquisition is seen as strategically and financially attractive, enhancing Boston Scientific's capabilities in high-growth segments such as mechanical thrombectomy and neurovascular [5][6] - **Cultural Alignment**: Both companies share a strong cultural alignment focused on innovation and clinical evidence, which is expected to enhance patient care [6][19] - **Financial Impact**: The deal is expected to be slightly dilutive to Boston Scientific's adjusted operating margin in the first year post-close, neutral to slightly accretive in the second year, and increasingly accretive thereafter [12][13] - **Revenue Growth Expectations**: Penumbra is projected to contribute to Boston Scientific's goal of over 10% compounded annual growth from 2026 to 2028 [13] Financial Details - **Transaction Structure**: The acquisition will be funded with approximately $11 billion in cash and $4 billion in stock, resulting in a 73% cash and 27% stock mix [11] - **EPS Impact**: The acquisition is expected to dilute adjusted EPS by $0.06-$0.08 in the first year, with a return to accretion in subsequent years [12][46] - **Synergies**: Anticipated synergies include over $200 million in operational impact from revenue synergies and cost efficiencies by year three [12][25] Additional Important Content - **Market Expansion**: The acquisition allows Boston Scientific to enter new high-growth segments and leverage its global commercial footprint to enhance Penumbra's market reach [5][14] - **Retention of Key Staff**: Boston Scientific emphasizes the importance of retaining Penumbra's key employees and maintaining its innovative culture post-acquisition [51][53] - **Future M&A Considerations**: Boston Scientific remains open to future acquisitions but will be prudent given the size of the Penumbra deal [29][28] - **Regulatory Process**: The acquisition is expected to close in 2026, subject to customary closing conditions [7][20] This summary encapsulates the key points from the Boston Scientific investor update regarding the acquisition of Penumbra, highlighting strategic, financial, and operational aspects of the deal.